Compare AVD & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVD | PMN |
|---|---|---|
| Founded | 1969 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4M | 84.1M |
| IPO Year | 1995 | 2022 |
| Metric | AVD | PMN |
|---|---|---|
| Price | $1.41 | $9.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $42.52 |
| AVG Volume (30 Days) | ★ 300.5K | 30.3K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $515,114,000.00 | N/A |
| Revenue This Year | $7.74 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.61 | $0.29 |
| 52 Week High | $5.53 | $27.40 |
| Indicator | AVD | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 15.12 | 33.13 |
| Support Level | N/A | $9.20 |
| Resistance Level | $2.41 | $15.37 |
| Average True Range (ATR) | 0.10 | 0.95 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 4.85 | 15.55 |
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. The company is a manufacturer of specialty solutions that develops and markets safe synthetic, biological, and biorational products for agricultural, commercial, and consumer uses. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.